DE122009000006I2 - Pharmazeutische kombination von ethinylestradiol und drospirenone als empfangnisverhutendes mittel. - Google Patents

Pharmazeutische kombination von ethinylestradiol und drospirenone als empfangnisverhutendes mittel.

Info

Publication number
DE122009000006I2
DE122009000006I2 DE200912000006 DE122009000006C DE122009000006I2 DE 122009000006 I2 DE122009000006 I2 DE 122009000006I2 DE 200912000006 DE200912000006 DE 200912000006 DE 122009000006 C DE122009000006 C DE 122009000006C DE 122009000006 I2 DE122009000006 I2 DE 122009000006I2
Authority
DE
Germany
Prior art keywords
drospirenone
pharmaceutical combination
ethinyl estradiol
contraceptive agent
daily dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE200912000006
Other languages
English (en)
Other versions
DE122009000006I1 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122009000006(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of DE122009000006I1 publication Critical patent/DE122009000006I1/de
Publication of DE122009000006I2 publication Critical patent/DE122009000006I2/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE200912000006 1999-08-31 2000-08-31 Pharmazeutische kombination von ethinylestradiol und drospirenone als empfangnisverhutendes mittel. Active DE122009000006I2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38627499A 1999-08-31 1999-08-31
EP99202826 1999-08-31
PCT/IB2000/001213 WO2001015701A1 (en) 1999-08-31 2000-08-31 Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive

Publications (2)

Publication Number Publication Date
DE122009000006I1 DE122009000006I1 (de) 2009-05-07
DE122009000006I2 true DE122009000006I2 (de) 2012-03-22

Family

ID=26153359

Family Applications (5)

Application Number Title Priority Date Filing Date
DE60042089T Expired - Lifetime DE60042089D1 (de) 1999-08-31 2000-08-31 Pharmazeutische Kombination von Ethinylestradiol und Drospirenon als empfängnisverhütendes Mittel
DE60041421T Expired - Lifetime DE60041421D1 (de) 1999-08-31 2000-08-31 Pharmazeutische Kombination von Ethinylestradiol und Drospirenon als empfängnisverhütendes Mittel
DE200912000007 Active DE122009000007I2 (de) 1999-08-31 2000-08-31 Pharmazeutische kombination von ethinylestradiol und drospirenone als empfangnisverhutendes mittel.
DE200912000006 Active DE122009000006I2 (de) 1999-08-31 2000-08-31 Pharmazeutische kombination von ethinylestradiol und drospirenone als empfangnisverhutendes mittel.
DE60006692T Expired - Lifetime DE60006692T2 (de) 1999-08-31 2000-08-31 Pharmazeutische kombination von ethinylestradiol und drospirenone als empfängnisverhütendes mittel

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DE60042089T Expired - Lifetime DE60042089D1 (de) 1999-08-31 2000-08-31 Pharmazeutische Kombination von Ethinylestradiol und Drospirenon als empfängnisverhütendes Mittel
DE60041421T Expired - Lifetime DE60041421D1 (de) 1999-08-31 2000-08-31 Pharmazeutische Kombination von Ethinylestradiol und Drospirenon als empfängnisverhütendes Mittel
DE200912000007 Active DE122009000007I2 (de) 1999-08-31 2000-08-31 Pharmazeutische kombination von ethinylestradiol und drospirenone als empfangnisverhutendes mittel.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60006692T Expired - Lifetime DE60006692T2 (de) 1999-08-31 2000-08-31 Pharmazeutische kombination von ethinylestradiol und drospirenone als empfängnisverhütendes mittel

Country Status (26)

Country Link
EP (4) EP2044941A1 (de)
JP (2) JP4354667B2 (de)
KR (2) KR101019361B1 (de)
AT (3) ATE254464T1 (de)
AU (4) AU780330B2 (de)
BG (1) BG66114B1 (de)
BR (1) BR0014159A (de)
CY (3) CY1108990T1 (de)
CZ (1) CZ300514B6 (de)
DE (5) DE60042089D1 (de)
DK (3) DK1380301T3 (de)
EE (1) EE05128B1 (de)
ES (3) ES2319750T3 (de)
HK (3) HK1047247B (de)
HR (1) HRP20070188B1 (de)
HU (1) HU227207B1 (de)
IL (1) IL148339A0 (de)
ME (2) ME00329B (de)
NO (1) NO326860B1 (de)
NZ (1) NZ517845A (de)
PL (1) PL199028B1 (de)
PT (3) PT1214076E (de)
RS (3) RS20090134A (de)
SI (3) SI1598069T1 (de)
TW (1) TWI276436B (de)
WO (1) WO2001015701A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1214076E (pt) * 1999-08-31 2004-04-30 Schering Ag Combinacao farmaceutica de etinilestradiol e drospirenona para utilizacao como um contraceptivo
JO2334B1 (en) * 2000-01-18 2006-06-28 باير شيرنغ فارما اكتنجيسيلشافت Drospirenone for hormone replacement therapy
SK287719B6 (en) * 2000-01-18 2011-07-06 Bayer Schering Pharma Ag Drospirenone for hormone replacement therapy
EP1216713A1 (de) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Zusammensetzungen von Estrogen-Zyklodextrin Komplexe
EP1353699B1 (de) * 2000-12-20 2012-02-01 Bayer Pharma Aktiengesellschaft Einschlusskomplexe von Drospirenone und Beta-Cyclodextrin
AU2003239162A1 (en) * 2002-04-26 2003-11-10 Schering Ag Treatment of hypertension in women receiving hormone replacement therapy
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
WO2005087194A1 (en) * 2004-03-10 2005-09-22 Schering Aktiengesellschaft Compositions comprising drospirenone molecularly dispersed
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
EP1625849A1 (de) * 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmazeutische Zubereitung enthaltend Drospirenon und Ethinylestradiol
US8216611B2 (en) * 2005-03-30 2012-07-10 Mylan Pharmaceuticals Ulc Combined-step process for pharmaceutical compositions
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
US8617597B2 (en) * 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
EP1900359A1 (de) * 2006-09-16 2008-03-19 KAIROSmed GmbH Mündliche modifizierte Entlassungsformulierungen enthaltend drospirenon und 8-prenylnaringenin für weiblicher Verhütung
EP2063870A2 (de) * 2006-09-16 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Orale formulierungen mit modifizierter freisetzung
AU2008235006A1 (en) * 2007-04-05 2008-10-16 Bayer Schering Pharma Aktiengesellschaft New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
HUP0700826A3 (en) 2007-12-20 2010-03-29 Richter Gedeon Nyrt Coated tablet containing drospirenone and process for producing the same
WO2009112231A2 (en) * 2008-03-10 2009-09-17 Schuermann Rolf New drospirenone/17beta-estradil regimen, pharmaceutical combination product and kit for performing this regimen
TW200946542A (en) * 2008-03-10 2009-11-16 Vladimir Hanes New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
WO2010094623A1 (en) 2009-02-18 2010-08-26 Bayer Schering Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
CN102985070A (zh) * 2010-04-15 2013-03-20 拜耳知识产权有限责任公司 用于hrt的极低剂量的固体口服剂型
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) * 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
IT202100008834A1 (it) 2021-04-08 2022-10-08 Ind Chimica Srl Processo per la preparazione di drospirenone come polvere fine tramite duplice cambio di forma cristallina
WO2023152658A1 (en) 2022-02-10 2023-08-17 Lupin Limited Slow release drospirenone tablet composition
WO2023165988A1 (en) * 2022-03-01 2023-09-07 Chemo Research, S.L. Chewable oral contraceptive

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3051168C2 (de) * 1979-01-24 1998-08-27 Minnesota Mining & Mfg Mono- bzw. Polycarbonsäureester oder deren Gemische oder Ester bzw. deren Gemische aus Isocyanaten und fluor- bzw. chlorhaltigen aliphatischen Alkoholen
DE3051166C2 (en) 1980-06-11 1990-10-18 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De Compsns. for contraception or treatment of gynaecological disorders
DE3347125A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
EP0209403B1 (de) * 1985-07-15 1991-10-23 Research Development Corporation of Japan Verfahren zur Herstellung von ultrafeinen organischen Verbindungen
DE3916112A1 (de) 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DK95093D0 (da) * 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
ZA939566B (en) * 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for dry blend compression od medicaments.
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4411585A1 (de) 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
AU700645B2 (en) * 1994-09-22 1999-01-14 N.V. Organon Process of making dosage units by wet granulation
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
KR100518102B1 (ko) * 1996-07-26 2005-10-04 와이어쓰 프로게스틴과 에스트로겐의 혼합물을 포함하는 단일상 피임약 키트
WO1998004267A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Progestin/estrogen oral contraceptive
DK0917466T3 (da) * 1996-07-26 2004-12-20 Wyeth Corp Oralt antikonceptionsmiddel
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
PT1214076E (pt) * 1999-08-31 2004-04-30 Schering Ag Combinacao farmaceutica de etinilestradiol e drospirenona para utilizacao como um contraceptivo
SK287719B6 (en) * 2000-01-18 2011-07-06 Bayer Schering Pharma Ag Drospirenone for hormone replacement therapy

Also Published As

Publication number Publication date
MEP36008A (en) 2011-02-10
CY1108990T1 (el) 2014-02-12
ME00329B (me) 2011-05-10
HU227207B1 (en) 2010-11-29
EP1214076B1 (de) 2003-11-19
HK1061968A1 (en) 2004-10-15
ES2325589T3 (es) 2009-09-09
ATE429231T1 (de) 2009-05-15
HRP20070188B1 (hr) 2015-06-19
RS20090134A (en) 2009-11-10
EP1214076A1 (de) 2002-06-19
HUP0202500A2 (en) 2002-10-28
EP1598069A3 (de) 2006-04-05
AU2009200247A1 (en) 2009-02-19
BR0014159A (pt) 2002-05-07
NO20020801L (no) 2002-04-26
AU2005202046B9 (en) 2008-12-11
EE05128B1 (et) 2009-02-16
KR100857344B1 (ko) 2008-09-05
KR101019361B1 (ko) 2011-03-07
DE60006692T2 (de) 2004-09-23
EE200200110A (et) 2003-06-16
DK1214076T3 (da) 2004-02-23
CY1109252T1 (el) 2014-07-02
CZ300514B6 (cs) 2009-06-03
PT1380301E (pt) 2009-03-30
AU2010226924A1 (en) 2010-10-28
AU2005202046B2 (en) 2008-11-20
HK1047247A1 (en) 2003-02-14
ES2211580T3 (es) 2004-07-16
PL199028B1 (pl) 2008-08-29
PT1214076E (pt) 2004-04-30
TWI276436B (en) 2007-03-21
NO20020801D0 (no) 2002-02-19
HUP0202500A3 (en) 2004-04-28
ATE420648T1 (de) 2009-01-15
CY2009015I2 (el) 2014-02-12
AU2009200247B2 (en) 2010-07-01
PL354406A1 (en) 2004-01-12
PT1598069E (pt) 2009-07-20
KR20020040798A (ko) 2002-05-30
DE60042089D1 (de) 2009-06-04
ES2319750T3 (es) 2009-05-12
YU14502A (sh) 2006-01-16
SI1380301T1 (sl) 2009-06-30
EP1598069B1 (de) 2009-04-22
SI1214076T1 (en) 2004-06-30
EP1380301A1 (de) 2004-01-14
HRP20070188A2 (en) 2007-07-31
WO2001015701A1 (en) 2001-03-08
DE122009000007I1 (de) 2009-05-07
KR20070067248A (ko) 2007-06-27
AU780330B2 (en) 2005-03-17
DK1598069T3 (da) 2009-07-06
JP2009143959A (ja) 2009-07-02
DK1380301T3 (da) 2009-04-20
DE122009000007I2 (de) 2011-07-21
ATE254464T1 (de) 2003-12-15
SI1598069T1 (sl) 2009-10-31
AU2005202046A1 (en) 2005-06-09
AU6589500A (en) 2001-03-26
CZ2002615A3 (cs) 2002-08-14
EP1598069A2 (de) 2005-11-23
HK1047247B (zh) 2004-07-23
HK1082432A1 (en) 2006-06-09
BG66114B1 (bg) 2011-05-31
JP2003508441A (ja) 2003-03-04
RS50262B2 (sr) 2018-10-31
IL148339A0 (en) 2002-09-12
EP2044941A1 (de) 2009-04-08
RS50262B (sr) 2009-07-15
NO326860B1 (no) 2009-03-02
DE60041421D1 (de) 2009-03-05
CY2009015I1 (el) 2014-02-12
NZ517845A (en) 2004-12-24
JP4354667B2 (ja) 2009-10-28
EP1380301B1 (de) 2009-01-14
DE122009000006I1 (de) 2009-05-07
DE60006692D1 (de) 2003-12-24

Similar Documents

Publication Publication Date Title
DE122009000007I2 (de) Pharmazeutische kombination von ethinylestradiol und drospirenone als empfangnisverhutendes mittel.
RU2005140938A (ru) Дроспиренон для гормональной заместительной терапии
AP2001002054A0 (en) Use of biogenic estrogen sulfamates for hormone replacement therapy.
CA1300017C (en) Composition for preventing osteoporosis
UA81387C2 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
EA200701091A1 (ru) Противозачаточный фармацевтический препарат
AU692155B2 (en) Method and composition for treatment of osteoporosis
TH54054B (th) สารผสมทางเภสัชกรรมสำหรับใช้เป็นยาคุมกำเนิด
AR025443A1 (es) Una composicion farmaceutica para ser usada como anticonceptivo.